BioSpace News Archive

Sixty-two percent of U.S. adults identify healthcare costs as a significant source of stress.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Bristol-Myers Squibb (NYSE: BMY) has dosed the first subject in a clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of BMS-986179

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today the launch of version 4.1 of its award-winning Dario® App for the Dario Blood Glucose Monitoring System

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced today that its Executive Chairman, Leonard Mazur, will present at the Dawson James 2018 Small Cap Growth Stock Conference.

Leveraging technology developed at the University of Rochester that was recently recognized with a Nobel Prize, Clerio Vision, Inc. is commercializing LIRIC—a novel, noninvasive method to correct human vision. .

Collaboration agreement to evaluate the combination of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC), in combination with the checkpoint inhibitor avelumab and/or an investigational Merck KGaA, Darmstadt, Germany DNA damage response (DDR) inhibitor, in patients with HER2 expressing or mutated solid tumors.

PeriGen, the innovator in perinatal early warning systems, will host a free educational webinar on Tuesday, October 30, outlining The Joint Commission’s new Perinatal Care (PC) performance measure, PC-06.

Kala Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology

A new study published in Obstetrics and Gynecology shows the method of cycle-tracking based on cycle length alone via apps cannot accurately predict ovulation for couples trying to conceive.

PrisMax incorporates advanced technology for continuous renal replacement therapy (CRRT) designed to increase accuracy and performance for critically ill patients